Sign up to save your podcasts
Or
Share Novo Nordisk's CEO Has a Comeback Plan
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Novo Nordisk's CEO Has a Comeback Plan
When Maziar Mike Doustdar took over as CEO of Novo Nordisk last year, the company had lost ground in the anti-obesity drug market. Doustdar spoke with Jessica Mendoza about his plans to turn the company around, the recent success of their Wegovy pill and what keeps him up at night.
Further Listening:
- Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
- Trillion Dollar Shot
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By The Wall Street Journal & Spotify Studios
4.2
56105,610 ratings
When Maziar Mike Doustdar took over as CEO of Novo Nordisk last year, the company had lost ground in the anti-obesity drug market. Doustdar spoke with Jessica Mendoza about his plans to turn the company around, the recent success of their Wegovy pill and what keeps him up at night.
Further Listening:
- Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
- Trillion Dollar Shot
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like The Journal.
View all
Planet Money
30,609 Listeners
WSJ Opinion: Potomac Watch
2,851 Listeners
WSJ Your Money Briefing
1,713 Listeners
WSJ What’s News
4,420 Listeners
Odd Lots
1,993 Listeners
WSJ Tech News Briefing
1,649 Listeners
The Daily
113,121 Listeners
WSJ Minute Briefing
686 Listeners
Up First from NPR
56,944 Listeners
Bold Names
1,448 Listeners
Wall Street Breakfast
1,044 Listeners
Post Reports
5,217 Listeners
Barron's Streetwise
1,573 Listeners
The Big Take
155 Listeners
Bad Bets
1,322 Listeners
WSJ Opinion: Free Expression
586 Listeners
As We Work
151 Listeners
WSJ's Take On the Week
150 Listeners